This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 20 Aug 2024
2 min

Head to Head Studies

Author: Sanofi

Editorial Team

Admelog® (insulin lispro 100 units/mL)  
Admelog logo

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Prescribing Information (GB only)

Head-to-head studies Admelog® vs Humalog®

Similar PK/PD profile chart

Similar PK/PD profile1

PK/PD profiles in the biosimilar, Admelog, were similar to the EU-approved Humalog in adult males with Type 1 diabetes1

Similar mean HbA1c reduction chart

Similar mean HbA1C reduction2,3

Similar mean HbA1C reduction from baseline to Week 26 in Admelog and Humalog groups, in both Type 1 and Type 2 diabetes2,3

Type 1 diabetes and Type 2 diabetes chart

Similar long-term safety and tolerability profiles2,3

Similar rates of patients with at least one hypoglycaemic event, regardless of the category, was observed in both Admelog and Humalog groups in Type 1 and Type 2 diabetes2,3

SEE MORE FROM SCIENCE

Admelog

Admelog is indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis and for the initial stabilisation of diabetes mellitus. 

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Patient Website

Find resources and support for your patients on Admelog®. Help patients understand the basics of living and staying well with diabetes and how to have a positive start and experience with the medication prescribed to them.

Get in touch with the Diabetes Team

MAT-XU-2201545 (v5.0) Date of Preparation: October 2023
References
  1. Kapitza C, et al. Diabetes Obes Metab. 2017;19(5):622–7
  2. Garg SK, et al. Diabetes Technol Ther. 2017;19(9):516–26
  3. Derwahl K, et al. Diabetes Technol Ther. 2018;20(1):1–10

MAT-XU-2300438 (v6.0) Date of Preparation: August 2024